REG - Proteome Sciences - Director/PDMR Shareholding

Proteome SciencesAnnouncement

21/04/2022 17:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220421:nRSU9662Ia&default-theme=true

RNS Number : 9662I  Proteome Sciences PLC  21 April 2022

 

 

 

 

 

 

 
21 April 2022

 

Proteome Sciences plc

("Proteome Sciences" or the "Company")

 

Director/PDMR Shareholding

 

The Company has received notification from Vulpes Investment Management Pte
Ltd ("Vulpes") that on 19 April 2022 it purchased 1,465,000 ordinary shares of
1p in the capital of the Company ("Ordinary Shares") at a price of 4p per
Ordinary Share (the "Purchase"). Following the Purchase, Vulpes has a total
direct and indirect interest in 67,291,194 Ordinary Shares, equivalent to
22.80% of Proteome Sciences' total issued share capital.

 

By virtue of Martin Diggle being a Director of both Vulpes and the Company, he
now has an interest in 67,291,194 Ordinary Shares of the Company representing
22.80% of the issued share capital of the Company.

 

The below notification is made in accordance with the requirements of the
Market Abuse (amendment) (EU Exit) Regulations 2019/310.

 

 1.            Details of the person discharging managerial responsibilities/person closely
               associated
 a)            Name:                                                         Martin Diggle
               Reason for the notification
 a)            Position/status:                                              Non-Executive Director
 b)            Initial notification/Amendment:                               Initial Notification
               Details of the issuer, emission allowance market participant, auction
               platform, auctioneer or auction monitor
 a)            Name:                                                         Proteome Sciences Plc
 b)            LEI:                                                          213800Q62ICXANKU2986
               Details of the transaction(s): section to be repeated for (i) each type of
               instrument; (ii) each type of transaction; (iii) each date; and (iv) each
               place where transactions have been conducted
 a)            Description of the financial instrument, type of instrument:  Ordinary Shares of 1p nominal value

               Identification code:                                          GB0003104196
 b)            Nature of the transaction:                                    Purchase of Ordinary Shares
 c)            Price(s) and volume(s):

Price(s)  Volume(s)
                                                                             4.00p     732,500
                                                                             4.00p     732,500

 
 d)            Aggregated information:                                       Single transaction as in 4 c) above

Average Price  Volume(s)
               ·    Aggregated volume:                                       4.00p          1,465,000

               ·    Price:
 
 e)            Date of the transaction:                                      19 April 2022
 f)            Place of the transaction:                                     London Stock Exchange, AIM (XLON)

 

d)

Aggregated information:

·    Aggregated volume:

·    Price:

Single transaction as in 4 c) above

 Average Price  Volume(s)
 4.00p          1,465,000

 

e)

Date of the transaction:

19 April 2022

f)

Place of the transaction:

London Stock Exchange, AIM (XLON)

 

For further information:

 

 Proteome Sciences plc
 Dr Ian Pike, Chief Scientific Officer     Tel: +44 (0)20 7043 2116

 Richard Dennis, Chief Commercial Officer

 Allenby Capital Limited (Nominated Adviser & Broker)
 John Depasquale / Jeremy Porter           Tel: +44 (0) 20 3328 5656

 

About Proteome Sciences plc. (www.proteomics.com (http://www.proteomics.com/)
)

Proteome Sciences plc is a specialist provider of contract proteomics services
to enable drug discovery, development and biomarker identification, and
employs proprietary workflows for the optimum analysis of tissues, cells and
body fluids.  SysQuant® and TMT®MS2 are unbiased methods for identifying
and contextualising new targets and defining mechanisms of biological
activity, while analysis using Super-Depletion and TMTcalibrator™ provides
access to over 8,500 circulating plasma proteins for the discovery of
disease-related biomarkers. Targeted assay development using mass spectrometry
delivers high sensitivity, interference-free biomarker analyses in situations
where standard ELISA assays are not available.

The Company has its headquarters in London, UK, with laboratory facilities in
Frankfurt, Germany.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHSEFFMFEESEFL